{
    "nct_id": "NCT02924376",
    "official_title": "A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)",
    "inclusion_criteria": "* Histologically or cytologically confirmed cholangiocarcinoma.\n* Radiographically measurable or evaluable disease per RECIST v1.1.\n* Tumor assessment for FGF/FGFR gene alteration status.\n* Documented disease progression after at least 1 line of prior systemic therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Life expectancy â‰¥ 12 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior receipt of a selective FGFR inhibitor.\n* History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.\n* Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.\n* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.",
    "miscellaneous_criteria": ""
}